Keywords: gsk, tykerb, shows, potential, breast, cancer, uk-based

GSK's Tykerb shows potential in breast cancer

Article | 11 June 2007

Print This

UK-based drug major GlaxoSmithKline says that the results from trials of its anticancer agent Tykerb (lapatinib), presented at this year's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in